Answers are grounded in this paper and cite their sources.
Cross-sectional survey reveals treatment variability in pediatric ITP, suggesting a need for improved decision-making.
Background Pediatric immune thrombocytopenia (ITP) is a heterogeneous disorder in which a subset of patients progresses to persistent or chronic disease requiring long‐term management. Despite established guidelines, substantial variability remains in diagnostic and therapeutic approaches. This study evaluated real‐world management practices for pediatric persistent and chronic ITP in Saudi Arabia. Methods A cross‐sectional survey was conducted in January 2025 among pediatric hematologists across academic, governmental, and private institutions. The survey assessed diagnostic strategies, including bone marrow aspiration (BMA) and immune workups, as well as treatment preferences between rituximab and splenectomy. Results Thirty‐one responses were analyzed. Routine BMA use was reported by 45.2% of respondents, despite recommendations favoring selective evaluation. Only 19.4% reported high confidence in interpreting immune workups. Rituximab was generally preferred over splenectomy, primarily due to concerns regarding infection risk and its nonsurgical nature. Although splenectomy was perceived as effective, its use remained limited. Conclusion Marked variability persists in the management of pediatric persistent ITP. Reducing unnecessary invasive procedures and strengthening shared decision‐making may improve alignment with evidence‐based practice. Targeted educational initiatives and clearer implementation strategies are needed to harmonize care and optimize outcomes.
No takes yet. Share an insight, caveat, or question.
Algiraigri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: